Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences

Rhea-AI Summary

Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on cancer treatment, will have its CEO Brian Sullivan participate in virtual investor meetings at two upcoming conferences. The 12th Annual Craig-Hallum Alpha Select Conference is scheduled for November 16, 2021, followed by the Jefferies London Healthcare Conference on November 18-19, 2021. Celcuity utilizes a unique CELsignia companion diagnostic platform to identify patients who could benefit from targeted therapies by analyzing live tumor cells.

MINNEAPOLIS, MN / ACCESSWIRE / November 9, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in virtual meetings with investors at the following conferences:

• 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021; and
• Jefferies London Healthcare Conference on November 18 - 19, 2021.

About Celcuity

Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company's therapeutic efforts are focused on developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can identify. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.

Contacts:

Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
763-392-0123

Westwicke ICR
Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886

SOURCE: Celcuity Inc.

View source version on accesswire.com:
https://www.accesswire.com/671987/Celcuity-to-Participate-in-Upcoming-Jefferies-and-Craig-Hallum-Investor-Conferences

FAQ

When will Celcuity participate in investor conferences?

Celcuity will participate in the 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021, and the Jefferies London Healthcare Conference on November 18-19, 2021.

Who is participating from Celcuity at the conferences?

Brian Sullivan, Chairman, CEO, and Co-founder of Celcuity, will participate in the virtual meetings.

What is Celcuity's focus in cancer treatment?

Celcuity focuses on developing molecularly targeted therapies and companion diagnostics to extend cancer patients' lives.

What is the CELsignia platform used for?

The CELsignia platform analyzes live patient tumor cells to identify groups of cancer patients likely to benefit from approved targeted therapies.